Navigation Links Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs into Top 5 and Posts Double-Digit Growth

NEW YORK, Aug. 14, 2013 /PRNewswire/ --, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter.

(Photo: )
(Photo: )

Top Five Drugs by Sales, Q2 2013Drug NameSales ($000)% Change (previousquarter)Abilify










-0.37%The move of Humira into the top five shifts both Eli Lilly's Cymbalta, and AstraZeneca's Crestor down one position. Cymbalta, which reaped over $4.4 billion in 2012 U.S. sales, goes off patent this December.

Top Five Sales Gains, Q2 2013Drug NameGain ($000)% Change (previousquarter)Humira










+9.40%Not only does Humira re-enter the top five drugs by sales, it also comes in at the number one spot in terms of sales growth. Enbrel, another TNF blocker, returns to positive growth after a slight drop in Q1. Abilify and Epogen round out the fourth and fifth spots in quarterly sales gains.

"The significant impact of TNF blockers on autoimmune disease activity is not only reflected in their varied indications such as rheumatoid arthritis, psoriasis and Crohn's disease, but also in their steady sales growth," said Philip Thornton, CEO of "Since the second quarter of 2012, Humira, Enbrel, and Remicade have all placed in the top ten with revenues in the $1 billion range."

Top Five Sales Losses, Q2 2013 Drug NameLoss ($000)% Change (previousquarter)Avonex Pen




-18.95%Advair Diskus






-14.37%Newer oral multiple sclerosis (MS) agents such as Novartis' Gilenya may now be impacting the use of injectable interferon such as Biogen Idec's Avonex, which loses significant growth this quarter. However, the news may not be all bad -- Biogen Idec also manufactures Tecfidera, the newest oral MS drug -- predicted to draw in over $3.5 billion in annual sales by 2017. Modafinil lost over 17 percent in sales gains in Q1 2013, and continues to slide this quarter.

Reckitt Benckiser's Suboxone for opiate dependence, now available only in the oral dissolvable film, drops close to $79 million. The sublingual tablet formulation of Suboxone, discontinued in March, can now be replaced with the generic version approved in February.

Detailed data on the top 100 drugs can be accessed at:

About is the leading online drug information resource with over nine million unique visitors per month (ComScore, June 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit:

Media Inquiries: Press Officer
(718) 395 2473

Read more news from


Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
2. Launches iOS and Android Mobile App to Empower Patients and Providers Alike
3. Releases Q4 Sales for Top 100 U.S. Drugs
4. Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
5. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to
6. Raritan Releases Dynamic Search User Interface on Amazon Web Services (AWS) Marketplace
7. Nutrastar Releases Second Quarter 2013 Results
8. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
9. Bekers Hospital Review Releases Report on State of Hospital Industry
10. Beckers Healthcare Releases Report on State of ASC Industry
11. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
Post Your Comments:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):